| Virus-like particle display of HER2 induces potent anti-cancer responses A Palladini, S Thrane, CM Janitzek, J Pihl, SB Clemmensen, ... Oncoimmunology 7 (3), e1408749, 2018 | 104 | 2018 |
| Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations P Nanni, L Landuzzi, MC Manara, A Righi, G Nicoletti, C Cristalli, ... Scientific Reports 9 (1), 12174, 2019 | 56 | 2019 |
| HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response A Palladini, G Nicoletti, A Lamolinara, M Dall’Ora, T Balboni, ML Ianzano, ... Oncotarget 8 (33), 54444, 2017 | 25 | 2017 |
| Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma M Carrabotta, MA Laginestra, G Durante, C Mancarella, L Landuzzi, ... Cancer research 82 (4), 708-720, 2022 | 19 | 2022 |
| Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression V Giusti, F Ruzzi, L Landuzzi, ML Ianzano, R Laranga, E Nironi, ... Oncogenesis 10 (11), 77, 2021 | 18 | 2021 |
| CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology V Giusti, K Scotlandi Journal of Cell Communication and Signaling 15 (4), 545-566, 2021 | 17 | 2021 |
| Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft L Landuzzi, A Palladini, C Ceccarelli, S Asioli, G Nicoletti, V Giusti, ... Scientific reports 11 (1), 1563, 2021 | 8 | 2021 |
| Virus-like particle display of HER2 induces potent anti-cancer responses. Oncoimmunology 7, e1408749 A Palladini, S Thrane, CM Janitzek, J Pihl, SB Clemmensen, ... | 7 | 2018 |
| Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells C Mancarella, V Giusti, G Caldoni, MA Laginestra, A Parra, L Toracchio, ... Cancer Gene Therapy 30 (9), 1285-1295, 2023 | 3 | 2023 |
| Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts L Landuzzi, ML Ianzano, C Ceccarelli, ED Oto, G Nicoletti, V Giusti, ... Cancer Research 78 (13_Supplement), 216-216, 2018 | 1 | 2018 |
| Preclinical Development of novel therapeutic approaches in models resistant to targeted therapies in HER2-positive mammary breast cancer V Giusti alma, 2019 | | 2019 |
| A novel virus-like particle vaccine presenting HER-2 extracellular domain elicits strong immune responses against mammary carcinoma A Palladini, S Thrane, CM Janitzek, J Pihl, SB Clemmensen, WA Jongh, ... Cancer Research 78 (13_Supplement), 716-716, 2018 | | 2018 |
| HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing with a novel VLP-display technology T Jørgensen, M Soegaard, A Palladini, S Thrane, CM Janitzek, J Pihl, ... | | 2018 |
| HER-2 isoform interaction in mammary carcinoma onset and progression A Palladini, M Dall’Ora, T Balboni, G Nicoletti, M Ianzano, R Laranga, ... Cancer Research 76 (14_Supplement), 1200-1200, 2016 | | 2016 |
